NurExone Biologic is developing exosome-based therapies to regenerate nerves and recover function after Central Nervous System injuries.
Joined May 2021
- Tweets180
- Following486
- Followers408
- Likes86
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Dear Colleagues and Friends,
It is our great pleasure to invite you to participate in this international meeting, weizmann.ac.il/conferences/E…
which will take place at the Weizmann Institute of Science, March 19-22, 2023 @Nano_FCM
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
@NBiologic $NRX announces securities issuing at approximately premium over current share price to settle EnerSpar's debts prior to RTO transaction; 170,195 shares are offered at a deemed price of C$0.80 per share
Read more
newsfilecorp.com/release/135…
#TSXV #StocksToBuy #stockstowatch
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Press Release: @NBiologic | $NRX
NurExone announces #securities issuing at approximately a 100% #premium over current share price to #settle EnerSpar's #debts prior to its #RTO transaction; offers 170,195 shares at a deemed price of C$0.80.
PR Link: bit.ly/3CMin5s
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Calling all experts on #ExtracellularVesicles: your input is requested by Friday, August 26 on the next #MISEV (minimal information for studies of EVs) coordinated by @IsevOrg @lodrisc1 @GoberdhanD @Joadwe How can you get involved?
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
@NBiologic is featured among 4 promising Biotech companies in @FXEmpirecom.
fxempire.com/forecasts/artic…
#tsxv #stocktowatch @FXEmpireAnalyse @FXEmpireNews
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
@NBiologic signed an agreement with @yissumhuji
and Prof Tal Burstyn-Cohen @tbclab to evaluate compositions and methods to enhance the cellular uptake of particles using a unique small molecule. news.yahoo.com/nurexone-exos…
#exosomes
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
We are happy to share that @NBiologic recently signed a collaboration agreement with Polyrizon, an Israeli biotech company that specializes in innovative intranasal products.
finance.yahoo.com/news/nurex…
#exosomes #collaboration
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
@NBiologic is featured in the Healthtech section of @TechBullion! @liorshal
techbullion.com/nurexone-beg…
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Press Release: @NBiologic | $NRX
NurExone provides corporate update on its development of a #technology #drug platform for a bio-guided #exosome-based #product known as #ExoTherapy to treat #spinalcordinjuries.
PR Link: bit.ly/3uEU5FR
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Jerusalem Post recently covered NurExone as one of three new #Israeli #IPOs they are ‘excited about’. @NBiologic works with multiple Israeli universities to create their proprietary #Exosome-based #technology treatment.
Read more: bit.ly/3bYZ2mu
$NRX #biotech
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
39 years ago today, Rose Johnstone discovered extracellular vesicles for the first time, while studying sheep reticulocytes. It is truly a day to be appreciated by all EV researchers.
Happy birthday to extracellular vesicles!
#extracellularvesicles
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Finally!! RTO is completed and we are now listed on #TSXV under the trading symbol #NRX
finance.yahoo.com/news/nurex…
#extracellularvesicles #exosomes #spinalcordinjury #market #goingpublic #trade #rto #transactions
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
Thank you #Zerohedge for featuring @NBiologic and our recent RTO in this article!
zerohedge.com/news/2022-06-0…
#rto #tsxv #exosomes #exosome #extracellularvesicles #market
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
The global exosomes market is expected to reach USD 2 billion by 2030. @NBiologic is developing an exosomes-based technology drug platform to treat damage in the Central Nerve System. Happy to be part of this revolution!
Read more:
digitaljournal.com/pr/exosom…
NurExone Biologic (TSXV: NRX) (Germany: J90) retweeted
@NBiologic uses intranasal administration wherein exosomes can pass the BBR and are better retained in injury sites. Also, they are loadable with an array of therapeutic cargos for specific diseases. #biotech #biomed #pharma
